CoChat
Sign Up
Cited by 126Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial

Guo, Wen, Tian, Wenjun, Lin, Lu, Xu, Xiangjin·2020·Diabetes Research and Clinical Practice
DOI 10.1016/j.diabres.2020.108487
Open this paper in CoChat — free account

Abstract

Background Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD). More and more attention has been paid to the efficacy of liraglutide in the treatment of NAFLD, but the clinical evidence is still insufficient. Objective The purpose of this study was to use proton magnetic resonance spectroscopy (H-MRS) assessment of metformin alone poor blood glucose control of obese patients type 2 diabetes with NAFLD, added with insulin glargine, liraglutide or placebo effect in improving the fatty liver. Methods This is a 26-week, single-center, prospective, randomized placebo-controlled study. From September 2016 to July 2018, 128 patients with type 2 diabetes and NAFLD were enrolled in the China joint logistics team 900 hospital. The primary endpoints were the changes in intrahepatic content of lipid (IHCL), abdominal adiposity [subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)], from baseline to week 26 (end of treatment) and the changes in liraglutide group or insulin glargine group versus change in placebo group. Secondary endpoints included the changes in liver function (AST and ALT), glycemia (HbA1c and FPG), body weight, and BMI. Results A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo. After 26 weeks of treatment, compared to the placebo group, in the liraglutide and insulin glargine groups, IHCL…

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2020.108487

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests.

    “Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”

    From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [147]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Guo, W., Tian, W., Lin, L., & Xu, X.
Affiliations
Fujian Medical University (CN)
Corresponding author
Xu, Xiangjin
ORCID
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2020-12
Volume
170
Pages
108487
ISSN
0168-8227 (ISSN-L)
DOI
10.1016/j.diabres.2020.108487
OpenAlex
W3092443860
Cited by
126
References
6
Citations by year
2026: 24 · 2025: 28 · 2024: 28 · 2023: 22 · 2022: 18 · 2021: 5
FWCI
8.06
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Funders
Natural Science Foundation of Fujian Province
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, insulin glargine, non-alcoholic fatty liver disease, type 2 diabetes, hepatic steatosis, obesity, subcutaneous adipose tissue, visceral adipose tissue, glycemic control, metformin, GLP-1 receptor agonists, insulin therapy, liver function, body weight
MeSH terms
Insulin Glargine, Liraglutide, Adult, Blood Glucose, Body Weight, China, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Male, Metformin, Middle Aged, Obesity, Prospective Studies, Weight Loss, Treatment Outcome, Subcutaneous Fat, Intra-Abdominal Fat, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review